"Designing Growth Strategies is in our DNA"

Neurodegenerative Diseases Drugs Market Size, Share and Industry Analysis By Drug Class (Immunomodulator, Interferons, Decarboxylase Inhibitors, Dopamine Agonists, Others), By Disease Indication (Multiple Sclerosis, Parkinson’s Disease, Alzheimer's Disease, Spinal Muscular Atrophy (SMA), Others), By Route of Administration (Oral, Injection, Transdermal, Others), By End User and Regional Forecast 2019-2026

Region : Global | Format: PDF | Report ID: FBI100661

 

Table of Content:

1. Introduction

1.1. Research Scope

1.2. Market Segmentation

1.3. Research Methodology

1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities 

3.4  Market Trends

4. Key Insights

4.1 Prevalence ofNeurodegenerative Diseases - For Key Countreis, 2018

4.2 Regulatory Scenario - For KeyCountries

4.3 Patent Snapshot

4.3 New Product Launch

4.4 Pipeline Analysis

4.5 Key Industry Developments -Mergers, Acquisitions and Partnerships

5. GlobalNeurodegenerative Diseases Drugs Market Analysis, Insights and Forecast,2015-2026

5.1. Key Findings / Summary

5.2. Market Analysis, Insightsand Forecast – By Drug Class

5.2.1Immunomodulators

5.2.2Interferons 

5.2.3Decarboxylase Inhibitors

5.2.4 DopamineAgonists

5.2.4 Others

5.3. Market Analysis, Insightsand Forecast – By Disease Indication

5.3.1 MultipleSclerosis

5.3.2Parkinson’s Disease

5.3.3Alzheimer's Disease

5.3.4 SpinalMuscular Atrophy (SMA)

5.3.5 Others

5.4. Market Analysis, Insightsand Forecast – By Route of Administration

5.4.1 Oral

5.4.2Injection

5.4.3Transdermal

5.5. Market Analysis, Insightsand Forecast – By Distribution Channel

5.5.1 HospitalPharmacy

5.5.2 RetailPharmacy

5.5.3 OnlinePharmacy

5.6. Market Analysis, Insightsand Forecast – By Region

5.6.1 NorthAmerica

5.6.2 Europe

5.6.3 Asia Pacific 

5.6.4 LatinAmerica

5.6.5 MiddleEast & Africa

6. North AmericaNeurodegenerative Diseases Drugs Market Analysis, Insights and Forecast,2015-2026

6.1. Key Findings / Summary

6.2. Market Analysis – By DrugClass

6.2.1Immunomodulators

6.2.2Interferons 

6.2.3Decarboxylase Inhibitors

6.2.4 DopamineAgonists

6.2.4 Others

6.3. Market Analysis, Insightsand Forecast – By Disease Indication

6.3.1 MultipleSclerosis

6.3.2Parkinson’s Disease

6.3.3Alzheimer's Disease

6.3.4 SpinalMuscular Atrophy (SMA)

6.3.5 Others

6.3. Market Analysis – By Routeof Administration

6.4.1 Oral

6.4.2Injection

6.4.3Transdermal

6.4. Market Analysis – ByDistribution Channel

6.5.1 HospitalPharmacy

6.5.2 RetailPharmacy

6.5.3 Online Pharmacy

6.5. Market Analysis – By Country

6.6.1 U.S.

6.6.2 Canada

7. EuropeNeurodegenerative Diseases Drugs Market Analysis, Insights and Forecast,2015-2026

7.1. Key Findings / Summary

7.2. Market Analysis – By DrugClass

7.2.1Immunomodulators

7.2.2Interferons 

7.2.3Decarboxylase Inhibitors

7.2.4 DopamineAgonists

7.2.4 Others

7.3. Market Analysis, Insightsand Forecast – By Disease Indication

7.3.1 MultipleSclerosis

7.3.2Parkinson’s Disease

7.3.3Alzheimer's Disease

7.3.4 SpinalMuscular Atrophy (SMA)

7.3.5 Others

7.4. Market Analysis – By Routeof Administration

7.4.1 Oral

7.4.2Injection

7.4.3Transdermal

7.5. Market Analysis – ByDistribution Channel

7.5.1  Hospital Pharmacy

7.5.2 RetailPharmacy

7.5.3 OnlinePharmacy

7.6. Market Analysis – ByCountries/ Sub regions

7.6.1 U.K.

7.6.2 Germany

7.6.3 France

7.6.4 Italy

7.6.5 Spain

7.6.6Scandinavia 

7.6.7 Rest ofEurope

8. Asia PacificNeurodegenerative Diseases Drugs Market Analysis, Insights and Forecast,2015-2026

8.1. Key Findings / Summary

8.2. Market Analysis – By DrugClass

8.2.1Immunomodulators

8.2.2Interferons 

8.2.3Decarboxylase Inhibitors

8.2.4 DopamineAgonists

8.2.4 Others

8.3. Market Analysis, Insightsand Forecast – By Disease Indication

8.3.1 MultipleSclerosis

8.3.2Parkinson’s Disease

8.3.3Alzheimer's Disease

8.3.4 SpinalMuscular Atrophy (SMA)

8.3.5 Others

8.4. Market Analysis – By Routeof Administration

8.4.1 Oral

8.4.2Injection

8.4.3 Transdermal

8.5. Market Analysis – ByDistribution Channel

8.5.1  Hospital Pharmacy

8.5.2 RetailPharmacy

8.5.3 OnlinePharmacy

8.6. Market Analysis – ByCountries/ Sub regions

8.6.1 Japan

8.6.2 China

8.6.3 India

8.6.4Australia

8.6.5Southeast Asia 

8.6.6 Rest ofAsia Pacific

9. Latin AmericaNeurodegenerative Diseases Drugs Market Analysis, Insights and Forecast,2015-2026

9.1. Key Findings / Summary

9.2. Market Analysis – By DrugClass

9.2.1Immunomodulators

9.2.2Interferons 

9.2.3Decarboxylase Inhibitors

9.2.4 DopamineAgonists

9.2.4 Others

9.3. Market Analysis, Insightsand Forecast – By Disease Indication

9.3.1 MultipleSclerosis

9.3.2Parkinson’s Disease

9.3.3Alzheimer's Disease

9.3.4 SpinalMuscular Atrophy (SMA)

9.3.5 Others

9.4. Market Analysis – By Routeof Administration

9.4.1 Oral

9.4.2Injection

9.4.3Transdermal

9.5. Market Analysis – ByDistribution Channel

9.5.1 HospitalPharmacy

9.5.2 RetailPharmacy

9.5.3 OnlinePharmacy

9.6. Market Analysis – ByCountries/ Sub regions

9.6.1 Brazil

9.6.2 Mexico

9.6.3 Rest ofLatin America

10. Middle East &Africa Neurodegenerative Diseases Drugs Market Analysis, Insights and Forecast,2015-2026

10.1. Key Findings / Summary

10.2. Market Analysis – By DrugClass

10.2.1Immunomodulators

10.2.2 Interferons 

10.2.3Decarboxylase Inhibitors

10.2.4Dopamine Agonists

10.2.4 Others

10.3. Market Analysis, Insightsand Forecast – By Disease Indication

10.3.1Multiple Sclerosis

10.3.2Parkinson’s Disease

10.3.3Alzheimer's Disease

10.3.4 SpinalMuscular Atrophy (SMA)

10.3.5 Others

10.4. Market Analysis – By Routeof Administration

10.4.1 Oral

10.4.2Injection

10.4.3Transdermal

10.5. Market Analysis – ByDistribution Channel

10.5.1Hospitals

10.5.2 RetailPharmacy

10.5.3 OnlinePharmacy

10.6. Market Analysis – ByCountries/ Sub regions

10.6.1 SouthAfrica

10.6.2 GCC

10.6.3 Rest ofMiddle East & Africa

11. CompetitiveAnalysis 

11.1. Key Industry Developments

11.2. Global Market ShareAnalysis (2018)

11.3. Competition Dashboard

11.4. Comparative Analysis –Major Players

11.5. Company Profiles (Overview,Drug Classs & services, SWOT analysis, Recent developments, strategies,financials (based on availability))

11.5.1 Biogen

11.5.2 Pfizer,Inc.

11.5.3 F.Hoffmann-La Roche Ltd

11.5.4 Merck& Co., Inc.

11.5.5Novartis AG

11.5.6 Sanofi

11.5.7 TevaPharmaceutical Industries Ltd.

11.5.8 OrionPharma

11.5.9 UCB S.A

11.5.10 ACADIAPharmaceuticals Inc.

11.5.11 H.Lundbeck A/S

11.5.12Mitsubishi Tanabe Pharma Corporation

11.5.13 OtherProminent Players

12. StrategicRecommendations

 class=
  • Jun, 2019
  • 2018
  • 2015-2017
  • 166

    CHOOSE LICENSE TYPE

  • 4850
    6850
    8850

Healthcare Clients

3M
abbvie
Amgen
Ansell
Fresenius
Galemed
Grifols
Ipsos
iqvia
Johnson
Jubilant
Lek
Pfizer
Roche
Siemens Healthineers
Styker
uniliver

Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X